RecruitingNCT06263530

Prognostic Significance of ctDNA in HL

Prognostic Significance of Circulating Tumor DNA in Hodgkin Lymphoma

Sponsor

Interni hematologicka klinika FNKV

Enrollment

500 participants

Start Date

Jan 2, 2022

Study Type

OBSERVATIONAL

Conditions

Prognostic Cancer Model

Summary

Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age \<60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse, during brentuximab vedotin and/or nivolumab treatment. Circulating tumor DNA will be correlated with the extent of tumor mass and chemo/radiotherapy.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at whether a blood test called ctDNA — which detects tiny fragments of tumor DNA circulating in the bloodstream — can help predict how well patients with Hodgkin lymphoma will respond to treatment. Hodgkin lymphoma is a cancer that affects the lymphatic system, which is part of the immune system. The ctDNA test is non-invasive and may one day help doctors personalise treatment plans. **You may be eligible if...** - You are 18 or older - You have just been newly diagnosed with classical Hodgkin lymphoma, confirmed by a biopsy - You are willing to participate and can sign an informed consent form **You may NOT be eligible if...** - You are unwilling or unable to sign the informed consent form - You have a form of Hodgkin lymphoma other than the classical type Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.